A recent meta-analysis of six studies of mumps vaccine effectiveness conducted in the U.S. found protection against mumps lasts an average of 27 years after the last dose of the vaccine.
The Centers for Disease Control and Prevention advisory committee has voted 12-2 to recommend FluMist, the nasal spray version of the influenza vaccine, be used during the 2018-19 influenza (flu) season.
Discontinuation of the product is due to the preference among healthcare professionals and patients for newer, more advanced immune globulin options.
A study examined whether the vaccine schedule was associated with an increased risk of infections not targeted by vaccines and found no statistically significant differences in estimated cumulative vaccine antigen exposure through the first 23 months of life.
This first-ever prospective economic analysis by Canadian investigators found that home-based subcutaneous immune globulin (SCIG) therapy was associated with significantly lower average total nondrug costs than hospital-based intravenous immune globulin (IVIG) therapy for patients with primary immunodeficiency disorders.
The U.S. Food and Drug Administration has approved Shire’s VONVENDI, a recombinant von Willebrand factor treatment for perioperative management of bleeding in adults 18 years and older with von Willebrand disease.
The World Health Organization is recommending a single dose of the typhoid conjugate vaccine for use in infants and children older than 6 months and a catch-up vaccine in children up to 15 years in countries where the infection is endemic.
The U.S. Food and Drug Administration approved Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), the first biosimilar drug to treat cancer.
GlaxoSmithKline's Nucala (mepolizumab) has been approved by the U.S. Food and Drug Administration to treateosinophilic granulomatosis with polyangiitis (EGPA).
The Centers for Medicare and Medicaid Services (CMS) is providing new policy guidance to help states design demonstration projects that promote the objectives of the Medicaid program and are consistent with federal statutory requirements.
An Internet panel survey of healthcare personnel (HCP) showed the overall influenza vaccination coverage estimate among HCP was 78.6 percent in the 2016-17 season, an increase of 15 percentage points since the 2010-11 season, but similar to the 2013-14 through 2015-16 seasons, with the highest coverage among those whose workplace had vaccination requirements.
Japanese drug maker Shionogi has created an experimental compound delivered via a single-dose pill that has been shown to effectively kill the influenza (flu) virus in patients within a single day.
